[1] 胡爱荣, 蒋素文, 胡耀仁. 肝硬化急性肾损伤及肝肾综合征的诊治路径. 中华危重病急救医学, 2016, 28:193-199.
[2] 尹伟, 李成忠. 特利加压素治疗肝肾综合征的疗效、预后及相关影响因素. 肝脏, 2016, 21:100-104.
[3] 中国中西医结合学会消化系统疾病专业委员会. 肝硬化中西医结合诊疗共识. 中国中西医结合消化杂志, 2011, 19:277-279.
[4] Angeli P, Gines P. Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice. J Hepatol, 2012, 57:1135-1140.
[5] Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology, 2016, 63:983-992.
[6] 游佳, 江家骥. 特利加压素治疗失代偿期肝硬化并发低钠血症的机制和处理原则. 临床肝胆病杂志, 2016, 32:2191-2194.
[7] Zhang Z, Maddukuri G, Jaipaul N, et al. Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin. J Crit Care, 2015, 30:969-974.
[8] 李中奇. 不同剂量特利加压素在肝硬化合并1型肝肾综合征中的效果. 临床医学, 2015, 35:54-55. |
